Enimmune Corporation (6564.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$15.20 (-5.30%) as of
Key statistics
- Market cap
- 1.10B
- EPS (TTM)
- -1.68
- Dividend yield
- 0.00%
- 52-week range
- 14.90 – 22.55
- Beta
- 0.24
- Revenue (TTM)
- 53.45M
- Profit margin
- -226.16%
- Volume
- 93.33k
About Enimmune Corporation
Enimmune Corporation engages in the research, development, and sale of drugs in Taiwan. The company offers EnVAX-A71, AimFlu-S(QIS), tetanus vaccine adsorbed suspension for injection, COVID-19 Ag rapid test, vaccines, test reagents, and related western medicines, as well as biotechnology services. It is also involved in the development of vaccines for the prevention of infectious diseases, including pneumococcus, norovirus, dengue fever virus, and Middle East respiratory syndrome, such as cell culture-derived Japanese encephalitis vaccine, which is in pre-clinical stage for the treatment of Japanese encephalitis virus; EV71+CA16 bivalent vaccine, which is in research stage for the treatment of hand-foot-mouth disease caused by Coxsackie A virus and enterovirus 71; and Anti-RBD monoclonal antibody, a murine monoclonal antibody for the recognition of receptor binding domain of the SARS-CoV-2 spike protein. The company was founded in 2014 and is based in Taipei, Taiwan. Enimmune Corporation is a subsidiary of Adimmune Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.